Resveratrol cancer study
This article was originally published in The Tan Sheet
Executive SummaryNCI-funded trial on red wine compound for cancer prevention will begin in January at England's University of Leicester with $1.7 mil. grant. Sequential trial features three phases: healthy volunteers will receive one-time 500 mg dose so researchers can measure blood levels of resveratrol, determine cancer fighting markers and doses for remainder of study. Second healthy group will receive daily resveratrol for 28 days with similar endpoints. In third group, patients with colon tumors will be dosed seven days prior to surgery, with tumor material tested for drug levels post-op. Leicester's U.S. partner University of Michigan will host some trial activity. Study completion expected by 2004...
You may also be interested in...
US investigators fan out to non-China inspection priorities and Secretary Azar talks supply management; warning letters hit record keeping, investigations and basic GMP compliance.
Mallinckrodt to pay $1.6bn and place its generics unit in bankruptcy under agreement in principle for US global settlement; six states are not on board, including New York, whose suit is still set to go to trial March 20.
The company has reached a broad opioid settlement agreement in principle under which its specialty generics subsidiaries would file for Chapter 11 bankruptcy and Mallinckrodt's branded business would operate separately.